Discontinued — last reported Q2 '25
Current Assets
Finished goods
Pfizer Finished goods increased by 8.7% to $4.49B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 36.7%, from $3.28B to $4.49B. Over 4 years (FY 2020 to FY 2024), Finished goods shows an upward trend with a 7.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ3 2017
Last reportedQ2 2025
Parent metricInventories
How to read this metric
An increase relative to sales may signal slowing demand or overproduction; a decrease may indicate strong sales or supply chain constraints.
Detailed definition
This represents the value of inventory that has completed the manufacturing process and is ready for sale to customers....
Peer comparison
Standard inventory metric for all manufacturing and retail companies.
Metric ID:
inv_finished_goodsHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.70B | $3.28B | $3.64B | $3.63B | $3.22B | $3.16B | $2.60B | $2.66B | $3.05B | $2.89B | $3.50B | $3.49B | $3.22B | $3.28B | $3.78B | $4.16B | $4.13B | $4.49B |
| QoQ Change | — | -11.4% | +11.0% | -0.2% | -11.4% | -1.9% | -17.6% | +2.1% | +14.7% | -5.1% | +20.9% | -0.1% | -7.8% | +1.9% | +15.1% | +10.3% | -0.9% | +8.7% |
| YoY Change | — | — | — | — | -13.0% | -3.7% | -28.5% | -26.9% | -5.3% | -8.5% | +34.3% | +31.4% | +5.6% | +13.4% | +8.0% | +19.2% | +28.1% | +36.7% |
| % of Inventories | 377.4% | 350.8% | 40.2% | 406.4% | 341.4% | 95.0% | 29.0% | 47.3% | 51.9% | 204.2% | 34.3% | 103.9% | 110.3% | 118.6% | 34.8% | 149.0% | 174.8% | 209.4% |
| Share Change | — | -26.6pp | -310.6pp | +366.2pp | -65.0pp | -246.4pp | -66.0pp | +18.3pp | +4.6pp | +152.3pp | -169.9pp | +69.6pp | +6.5pp | +8.3pp | -83.8pp | +114.2pp | +25.8pp | +34.6pp |
Range$2.60B – $4.49B
CAGR+4.6%
Avg YoY Growth+6.5%
Median YoY Growth+6.8%
Finished goods at Other Companies
Frequently Asked Questions
- What is Pfizer's finished goods?
- Pfizer (PFE) reported finished goods of $4.49B in Q3 2025.
- How has Pfizer's finished goods changed year-over-year?
- Pfizer's finished goods increased by 36.7% year-over-year, from $3.28B to $4.49B.
- What is the long-term trend for Pfizer's finished goods?
- Over 4 years (2020 to 2024), Pfizer's finished goods has grown at a 7.0% compound annual growth rate (CAGR), from $2.88B to $3.78B.
- What does finished goods mean?
- The value of completed products ready for sale.